User profiles for M. P. Cheng

Matthew P Cheng

McGill University
Verified email at mail.mcgill.ca
Cited by 15789

Diagnostic testing for severe acute respiratory syndrome–related coronavirus 2: a narrative review

MP Cheng, J Papenburg, M Desjardins… - Annals of internal …, 2020 - acpjournals.org
… To the editor, Cheng and colleagues review the essential role of diagnostic testing during
the COVID-19 pandemic1. We ask the question whether due to general under-recognition of …

[HTML][HTML] Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies

…, M Yanes-Lane, C Cao, DA Clifton, MP Cheng… - PLoS …, 2022 - journals.plos.org
Background Our understanding of the global scale of Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) infection remains incomplete: Routine surveillance data …

[HTML][HTML] Global seroprevalence of SARS-CoV-2 antibodies: a systematic review and meta-analysis

…, TG Evans, J Chevrier, J Papenburg, MP Cheng - PloS one, 2021 - journals.plos.org
Background Many studies report the seroprevalence of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) antibodies. We aimed to synthesize seroprevalence data to …

[HTML][HTML] A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19

…, M Abassi, NW Engen, MP Cheng… - New England journal …, 2020 - Mass Medical Soc
Background Coronavirus disease 2019 (Covid-19) occurs after exposure to severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the …

Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial

…, AA Nascene, KH Hullsiek, MP Cheng… - Annals of internal …, 2020 - acpjournals.org
Background: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).
Objective: To investigate whether hydroxychloroquine could reduce COVID-19 severity in …

[HTML][HTML] Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19

…, K Hager, A Mahmood, A Makarkov, MP Cheng… - Nature medicine, 2021 - nature.com
Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are being
deployed, but the global need greatly exceeds the supply, and different formulations might …

[HTML][HTML] Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial

…, FM Carrier, YA Cavayas, N Chagnon, MP Cheng… - Cmaj, 2022 - Can Med Assoc
Cheng also reports receiving personal fees from AstraZeneca, outside the submitted work;
and from Nplex Biosciences and GEn1E lifesciences (in the form of stock options for being a …

[HTML][HTML] SeroTracker: a global SARS-CoV-2 seroprevalence dashboard

…, T Yan, N Bobrovitz, J Chevrier, MP Cheng… - The Lancet Infectious …, 2021 - thelancet.com
As the initial phase of the COVID-19 pandemic passes its peak in many countries, serological
studies are becoming increasingly important in guiding public health responses. Antibody …

Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus 2: A Narrative Review

MP Cheng, CP Yansouni, NE Basta… - Annals of internal …, 2020 - acpjournals.org
Accurate serologic tests to detect host antibodies to severe acute respiratory syndrome–related
coronavirus 2 (SARS-CoV-2) will be critical for the public health response to the …

[HTML][HTML] Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis

…, G Butler-Laporte, EG McDonald, MP Cheng… - Clinical Microbiology …, 2022 - Elsevier
Background Precise estimates of mortality in Staphylococcus aureus bacteraemia (SAB) are
important to convey prognosis and guide the design of interventional studies. Objectives We …